Sugi Predict

Sugi Predict / Targets / C5AR1

C5AR1

C5a anaphylatoxin chemotactic receptor 1 · P21730 · C5AR1 on Sugi Atlas →

27,932 patent compounds predicted against C5AR1, 13,831 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL76388 SCHEMBL76388 0.50 18/20
SCHEMBL72862 SCHEMBL72862 0.50 15/20
SCHEMBL62072 SCHEMBL62072 0.54 14/20
SCHEMBL62140 SCHEMBL62140 0.54 14/20
SCHEMBL62282 SCHEMBL62282 0.52 13/20
SCHEMBL62535 SCHEMBL62535 0.50 12/20
SCHEMBL138028 SCHEMBL138028 0.40 12/20
SCHEMBL62063 SCHEMBL62063 0.50 10/20
SCHEMBL62326 SCHEMBL62326 0.50 10/20
SCHEMBL100940 SCHEMBL100940 0.42 10/20
SCHEMBL100215 SCHEMBL100215 0.38 10/20
SCHEMBL61247 SCHEMBL61247 0.50 9/20
SCHEMBL100437 SCHEMBL100437 0.38 9/20
SCHEMBL100990 SCHEMBL100990 0.37 9/20
SCHEMBL100199 SCHEMBL100199 0.37 9/20
SCHEMBL101230 SCHEMBL101230 0.36 9/20
SCHEMBL62198 SCHEMBL62198 0.60 8/20
SCHEMBL72945 SCHEMBL72945 0.60 8/20
SCHEMBL99985 SCHEMBL99985 0.40 8/20
SCHEMBL101247 SCHEMBL101247 0.35 8/20

Clinical trials — most relevant to C5AR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS PHASE4COMPLETED
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis PHASE3COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation PHASE3COMPLETED
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children PHASE3UNKNOWN
Ravulizumab and COVID-19 PHASE3UNKNOWN
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions PHASE3RECRUITING
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) PHASE2COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis PHASE2COMPLETED
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis PHASE2COMPLETED
Defibrotide TMA Prophylaxis Pilot Trial PHASE2COMPLETED
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 PHASE1COMPLETED
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair PHASE1WITHDRAWN
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
Complement C5a Receptors in Hidradenitis Suppurativa nanCOMPLETED
Complement Activation in the Lysosomal Storage Disorders nanWITHDRAWN
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target nanNOT_YET_RECRUITING
C5a Receptor Expression - COVID-19 (C5-COV) nanCOMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322) nanRECRUITING
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy nanCOMPLETED
A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis nanCOMPLETED
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia nanCOMPLETED
Effect of Platelet Storage on Complement Activation nanUNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Genetic Variation and Immune Responses After Injury nanUNKNOWN
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a C5AR1 binder may also engage these)

ProteinNameSimilarity
P79240 — 1.000 P79240 →
P79175 — 1.000 P79175 →
P30993 — 1.000 P30993 →
O70129 — 0.998 O70129 →
P79234 — 0.998 P79234 →
Q9TUE1 — 0.998 Q9TUE1 →
P79188 — 0.997 P79188 →
P30992 — 0.997 P30992 →
P97520 — 0.995 P97520 →
P79242 — 0.995 P79242 →
P79190 — 0.994 P79190 →
P79235 — 0.993 P79235 →
P0C7U4 — 0.993 P0C7U4 →
P79236 — 0.993 P79236 →
FPR2 N-formyl peptide receptor 2 0.990 landscape →
P79177 — 0.989 P79177 →
B9VR26 — 0.988 B9VR26 →
Q49SQ3 — 0.988 Q49SQ3 →
Q49SQ2 — 0.988 Q49SQ2 →
O88537 — 0.988 O88537 →
Q05394 — 0.988 Q05394 →
P79189 — 0.987 P79189 →
O88536 — 0.987 O88536 →
Q2WED0 — 0.987 Q2WED0 →
Q49SQ1 — 0.987 Q49SQ1 →
O35786 — 0.987 O35786 →
A4FUQ5 — 0.986 A4FUQ5 →
P79243 — 0.985 P79243 →
Q49SP8 — 0.985 Q49SP8 →
P79176 — 0.985 P79176 →